Patents by Inventor Tianying Zhang
Tianying Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11952666Abstract: A method for producing an abrasion-resistant coating on the inner wall of an aluminum alloy workpiece is provide. The steps include mixing a graphene powder and Al powder to obtain a mixed powder; combining and heating the mixed power with a polyvinyl alcohol (PVA) liquid, and performing spray granulation to obtain a low-temperature self-propagating composite; stirring a slurry comprising the low-temperature self-propagating composite and sodium silicate; injecting the slurry into a cylindrical inner cavity of an aluminum alloy workpiece mounted on a horizontal rotary table for rotation, the aluminum alloy workpiece is heated with the rotation at a second temperature of 80-100° C. so that the slurry is uniformly solidified on the cylindrical inner surface of the cylindrical inner cavity; and burning the slurry, after the slurry is uniformly solidified and while the rotation is maintained, with an oxyacetylene flame to form the wear-resistant coating.Type: GrantFiled: June 17, 2020Date of Patent: April 9, 2024Assignee: AECC BEIJING INSTITUTE OF AERONAUTICAL MATERIALSInventors: Haoliang Tian, Yang Yu, Changliang Wang, Mengqiu Guo, Zimin Zhou, Zhihui Tang, Ang Zhang, Yongjing Cui, Tianying Wang, Junguo Gao
-
Publication number: 20240000813Abstract: An adjuvant containing zinc aluminum risedronate, an immunogenic composition comprising the adjuvant and an immunogen, and uses of the adjuvant and the immunogenic composition.Type: ApplicationFiled: November 15, 2021Publication date: January 4, 2024Inventors: Qinjian ZHAO, Xiaofen HUANG, Meifeng NIE, Zhigang ZHANG, Quan YUAN, Tianying ZHANG, Shaowei LI, Ningshao XIA
-
Publication number: 20230323369Abstract: The present invention belongs to the field of virology, in particular to the field of hepatitis B virus treatment. Provided are a model and a method for screening HBV cccDNA inhibitors. According to the screening model and the method, the detection of a split luciferase is used as an alternative index ofHBV cccDNA detection, and a cccDNA-targeted drug can be screened in high throughput.Type: ApplicationFiled: June 24, 2021Publication date: October 12, 2023Applicants: XIAMEN UNIVERSITY, YANG SHENG TANG COMPANY, LTD.Inventors: Quan YUAN, Jiali CAO, Yali ZHANG, Mingfeng WANG, Jian MA, Tianying ZHANG, Jun ZHANG, Ningshao XIA
-
Publication number: 20230287086Abstract: Provided is a cell-penetrating peptide, which can deliver a variety of biological macromolecules, such as proteins, antibodies, nucleic acids and so on into cells across a membrane. In addition, further provided are a fusion protein, conjugate and complex containing the cell-penetrating peptide, and a use of the cell-penetrating peptide.Type: ApplicationFiled: July 13, 2021Publication date: September 14, 2023Inventors: Quan YUAN, Shaojuan WANG, Sheng NIAN, Min WEI, Yali ZHANG, Kai WANG, Yixin CHEN, Tianying ZHANG, Shengxiang GE, Ningshao XIA
-
Publication number: 20230218576Abstract: The present application relates to the field of antiviral treatment of hepatitis B, and specifically relates to the use of a compound represented by formula I in treatment against HBV virus.Type: ApplicationFiled: June 1, 2021Publication date: July 13, 2023Inventors: Tianying ZHANG, Jiali CAO, Tianshu SHI, Jian MA, Shaojuan WANG, Quan YUAN, Jun ZHANG, Ningshao XIA
-
Publication number: 20230174592Abstract: Disclosed are a fusion protein probe and a cell model for screening a blocking agent of coronavirus infections, a screening system comprising same, and a method of using the screening system for screening a blocking agent of coronavirus infections. The screening system and method do not involve live viruses, are simple and convenient to operate, have a high accuracy, are suitable for high throughput screening, and are of great significance for the development of coronavirus neutralizing antibodies, preventive vaccines, and small molecule drugs.Type: ApplicationFiled: April 30, 2021Publication date: June 8, 2023Applicants: YANG SHENG TANG COMPANY, LTD., XIAMEN UNIVERSITYInventors: Yali ZHANG, Shaojuan WANG, Yangtao WU, Wangheng HOU, Jianghui YE, Juan WANG, Tianying ZHANG, Tong CHENG, Quan YUAN, Ningshao XIA
-
Publication number: 20220251173Abstract: Antibodies (especially humanized antibodies) against the hepatitis B surface antigen (HBsAg), a nucleic acid molecule encoding same, a method for preparing same, and a pharmaceutical composition containing same. The anti-HBsAg antibodies have a higher binding affinity to HBsAg at a neutral pH than at an acidic pH, thereby significantly enhancing virus clearance efficiency and prolonging virus inhibition time. The antibodies and pharmaceutical composition may be used to prevent and/or treat HBV infections or diseases related to HBV infection (such as hepatitis B) for use in neutralizing the virulence of HBV in the body of a subject (such as a human) to reduce a serum level of HBV DNA and/or HBsAg in the body of the subject, or to activate a humoral immune response of a subject (such as a person infected with chronic HBV or a patient who has chronic hepatitis B) against HBV.Type: ApplicationFiled: May 22, 2020Publication date: August 11, 2022Applicants: XIAMEN UNIVERSITY, YANG SHENG TANG COMPANY, LTD.Inventors: Wenxin LUO, Yichao JIANG, Chao YU, Xiaoqing CHEN, Jixian TANG, Quan YUAN, Tianying ZHANG, Ningshao XIA
-
Publication number: 20220235117Abstract: Disclosed are antibodies to anti-hepatitis B surface antigen (HBsAg) (especially humanized antibodies), nucleic acid molecules encoding same, methods for preparing same, and pharmaceutical compositions containing same. The antibodies have higher affinity for HBsAg at neutral pH than at acidic pH, thereby significantly enhancing the virus clearance efficiency and prolonging the virus inhibition time. The antibodies and the pharmaceutical compositions can be used for preventing and/or treating HBV infections or diseases related to HBV infections (e.g., hepatitis B), for neutralizing the virulence of HBV in a subject (e.g., a human), for reducing the serum level of HBV DNA and/or HBsAg in the body of the subject, or for activating the humoral immune response of the subject (e.g., a chronic HBV infected or chronic hepatitis B patient) against HBV.Type: ApplicationFiled: May 22, 2020Publication date: July 28, 2022Applicants: XIAMEN UNIVERSITY, YANG SHENG TANG COMPANY, LTD.Inventors: Wenxin LUO, Can WEN, Xinchu XIANG, Jixian TANG, Yangtao WU, Tianying ZHANG, Quan YUAN, Ningshao XIA
-
Patent number: 10987418Abstract: The invention relates to a polypeptide carrier for presenting a target polypeptide, and use thereof. In particular, the invention relates to a nucleic acid molecule, comprising a nucleotide sequence encoding a polypeptide carrier, and being used for insertion of a nucleotide sequence encoding a target polypeptide. In addition, the invention further relates to a recombinant protein comprising the polypeptide carrier and a target polypeptide. Furthermore, the invention further relates to use of the nucleic acid molecule and the recombinant protein. In addition, the invention further relates to a vaccine or a pharmaceutical composition useful for preventing, alleviating or treating HBV infection or a disease associated with HBV infection (e.g., hepatitis B), comprising a recombinant protein comprising the polypeptide carrier of the invention and an epitope from HBV.Type: GrantFiled: February 5, 2018Date of Patent: April 27, 2021Assignees: XIAMEN UNIVERSITY, YANG SHENG TANG COMPANY, LTD.Inventors: Tianying Zhang, Quan Yuan, Xueran Guo, Minxi Wei, Xiaozhen Kang, Jun Zhang, Ningshao Xia
-
Patent number: 10689434Abstract: The invention provides an antibody (in particular, a humanized antibody) against hepatitis B surface antigen (HBsAg), a nucleic acid molecule encoding the same, a method for preparing the same, and a pharmaceutical composition comprising the same. The invention also provides use of the antibody and pharmaceutical composition. The antibody and pharmaceutical composition according to the invention can be used for preventing and/or treating HBV infection or a disease associated with HBV infection (such as Hepatitis B), for neutralizing HBV virulence in a subject (such as human), or for reducing the serum level of HBV DNA and/or HBsAg in a subject.Type: GrantFiled: October 9, 2016Date of Patent: June 23, 2020Assignees: XIAMEN UNIVERSITY, YANG SHENG TANG COMPANY, LTD.Inventors: Wenxin Luo, Bing Zhou, Juan Zhang, Quan Yuan, Tianying Zhang, Jun Zhang, Ningshao Xia
-
Publication number: 20200147205Abstract: The invention relates to a polypeptide carrier for presenting a target polypeptide, and use thereof. In particular, the invention relates to a nucleic acid molecule, comprising a nucleotide sequence encoding a polypeptide carrier, and being used for insertion of a nucleotide sequence encoding a target polypeptide. In addition, the invention further relates to a recombinant protein comprising the polypeptide carrier and a target polypeptide. Furthermore, the invention further relates to use of the nucleic acid molecule and the recombinant protein. In addition, the invention further relates to a vaccine or a pharmaceutical composition useful for preventing, alleviating or treating HBV infection or a disease associated with HBV infection (e.g., hepatitis B), comprising a recombinant protein comprising the polypeptide carrier of the invention and an epitope from HBV.Type: ApplicationFiled: February 5, 2018Publication date: May 14, 2020Applicants: XIAMEN UNIVERSITY, YANG SHENG TANG COMPANY, LTD.Inventors: Tianying ZHANG, Quan YUAN, Xueran GUO, Minxi WEI, Xiaozhen KANG, Jun ZHANG, Ningshao XIA
-
Patent number: 10548973Abstract: The invention relates to a polypeptide carrier for presenting a target polypeptide, and use thereof. In particular, the invention relates to a nucleic acid molecule, comprising a nucleotide sequence encoding a polypeptide carrier, and being used for insertion of a nucleotide sequence encoding a target polypeptide. In addition, the invention further relates to a recombinant protein comprising the polypeptide carrier and a target polypeptide. Furthermore, the invention further relates to use of the nucleic acid molecule and the recombinant protein. In addition, the invention further relates to a vaccine or a pharmaceutical composition useful for preventing, alleviating or treating HBV infection or a disease associated with HBV infection (e.g., hepatitis B), comprising a recombinant protein comprising the polypeptide carrier of the invention and an epitope from HBV.Type: GrantFiled: August 24, 2016Date of Patent: February 4, 2020Assignees: XIAMEN UNIVERSITY, YANG SHENG TANG COMPANY, LTD.Inventors: Tianying Zhang, Quan Yuan, Xueran Guo, Ying Zhang, Qinjian Zhao, Jun Zhang, Ningshao Xia
-
Publication number: 20190389939Abstract: The invention provides an antibody (in particular, a humanized antibody) against hepatitis B surface antigen (HBsAg), a nucleic acid molecule encoding the same, a method for preparing the same, and a pharmaceutical composition comprising the same. The invention also provides use of the antibody and pharmaceutical composition. The antibody and pharmaceutical composition according to the invention can be used for preventing and/or treating HBV infection or a disease associated with HBV infection (such as Hepatitis B), for neutralizing HBV virulence in a subject (such as human), or for reducing the serum level of HBV DNA and/or HBsAg in a subject.Type: ApplicationFiled: October 9, 2016Publication date: December 26, 2019Applicants: XIAMEN UNIVERSITY, YANG SHENG TANG COMPANY, LTD.Inventors: Wenxin LUO, Bing ZHOU, Juan ZHANG, Quan YUAN, Tianying ZHANG, Jun ZHANG, Ningshao XIA
-
Publication number: 20190247494Abstract: The invention relates to a polypeptide carrier for presenting a target polypeptide, and use thereof. In particular, the invention relates to a nucleic acid molecule, comprising a nucleotide sequence encoding a polypeptide carrier, and being used for insertion of a nucleotide sequence encoding a target polypeptide. In addition, the invention further relates to a recombinant protein comprising the polypeptide carrier and a target polypeptide. Furthermore, the invention further relates to use of the nucleic acid molecule and the recombinant protein. In addition, the invention further relates to a vaccine or a pharmaceutical composition useful for preventing, alleviating or treating HBV infection or a disease associated with HBV infection (e.g., hepatitis B), comprising a recombinant protein comprising the polypeptide carrier of the invention and an epitope from HBV.Type: ApplicationFiled: August 24, 2016Publication date: August 15, 2019Applicants: XIAMEN UNIVERSITY, YANG SHENG TANG COMPANY, LTD.Inventors: Tianying ZHANG, Quan YUAN, Xueran GUO, Ying ZHANG, Qinjian ZHAO, Jun ZHANG, Ningshao XIA
-
Patent number: 10246494Abstract: The present invention relates to epitope peptides (or mutants thereof) for treating hepatitis B virus infection, recombinant proteins comprising such epitope peptides (or mutants thereof) and carrier proteins, and uses of such epitope peptides (or mutants thereof) and recombinant proteins. The present invention also relates to antibodies against such epitope peptides, cell lines producing said antibodies, and uses thereof. Furthermore, the present invention relates to vaccines or pharmaceutical compositions for treating or alleviating one or more symptoms associated with hepatitis B virus infection, which comprise the recombinant proteins or antibodies according to the invention, respectively.Type: GrantFiled: July 14, 2017Date of Patent: April 2, 2019Assignees: Xiamen University, Yang Sheng Tang Company, Ltd.Inventors: Quan Yuan, Tianying Zhang, Wenxin Luo, Yixin Chen, Jun Zhang, Ningshao Xia
-
Publication number: 20180002382Abstract: The present invention relates to epitope peptides (or mutants thereof) for treating hepatitis B virus infection, recombinant proteins comprising such epitope peptides (or mutants thereof) and carrier proteins, and uses of such epitope peptides (or mutants thereof) and recombinant proteins. The present invention also relates to antibodies against such epitope peptides, cell lines producing said antibodies, and uses thereof. Furthermore, the present invention relates to vaccines or pharmaceutical compositions for treating or alleviating one or more symptoms associated with hepatitis B virus infection, which comprise the recombinant proteins or antibodies according to the invention, respectively.Type: ApplicationFiled: July 14, 2017Publication date: January 4, 2018Inventors: Quan Yuan, Tianying Zhang, Wenxin Luo, Yixin Chen, Jun Zhang, Ningshao Xia
-
Patent number: 9751914Abstract: The present invention relates to epitope peptides (or mutants thereof) for treating hepatitis B virus infection, recombinant proteins comprising such epitope peptides (or mutants thereof) and carrier proteins, and uses of such epitope peptides (or mutants thereof) and recombinant proteins. The present invention also relates to antibodies against such epitope peptides, cell lines producing said antibodies, and uses thereof. Furthermore, the present invention relates to vaccines or pharmaceutical compositions for treating or alleviating one or more symptoms associated with hepatitis B virus infection, which comprise the recombinant proteins or antibodies according to the invention, respectively.Type: GrantFiled: June 6, 2013Date of Patent: September 5, 2017Assignees: Xiamen University, Xiamen Innovax Biotech Co., Ltd.Inventors: Quan Yuan, Tianying Zhang, Wenxin Luo, Yixin Chen, Jun Zhang, Ningshao Xia
-
Publication number: 20150246948Abstract: The present invention relates to epitope peptides (or mutants thereof) for treating hepatitis B virus infection, recombinant proteins comprising such epitope peptides (or mutants thereof) and carrier proteins, and uses of such epitope peptides (or mutants thereof) and recombinant proteins. The present invention also relates to antibodies against such epitope peptides, cell lines producing said antibodies, and uses thereof. Furthermore, the present invention relates to vaccines or pharmaceutical compositions for treating or alleviating one or more symptoms associated with hepatitis B virus infection, which comprise the recombinant proteins or antibodies according to the invention, respectively.Type: ApplicationFiled: June 6, 2013Publication date: September 3, 2015Applicants: XIAMEN UNIVERSITY, XIAMEN INNOVAX BIOTECH CO., LTD.Inventors: Quan Yuan, Tianying Zhang, Wenxin Luo, Yixin Chen, Jun Zhang, Ningshao Xia